Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vanoxerine for recent onset atrial fibrillation or flutter
NCT02454283Phase 3Terminated
- Sponsor
- ChanRx
- Start
- Sep 2015
- Primary completion
- Nov 2015
- Modality
- Small Molecules
- Countries
- 5
01
Overview
A Phase 3 trial of vanoxerine in Atrial fibrillation (AFib), atrial flutter (AFL), sponsored by ChanRx. Started Sep 2015; status: terminated.
02
Drugs
vanoxerine
03
Conditions
Atrial fibrillation (AFib)atrial flutter (AFL)
Beyond the preview
Go deeper on NCT02454283.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02454283.